1
|
Bautista JD, Perales FJ, Ramis S, Montoya P, Riquelme I. Adaptation and Validation of a Serious Game for Motor Learning Training in Children with Cerebral Palsy. Games Health J 2023; 12:480-488. [PMID: 37449840 DOI: 10.1089/g4h.2023.0082] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 07/18/2023] Open
Abstract
Objective: Children with cerebral palsy (CP) present motor learning disorders and somatosensory dysfunction. Although many protocols use videogames in children with CP, few apply or examine motor learning principles. This study aims at (1) implementing therapist-user-designer collaboration in adapting a videogame to the principles of motor learning and the characteristics of users with CP, and (2) piloting the effectiveness of these adaptations by analyzing the achievement of motor learning parameters (learning rate acquisition, retention, and transfer to motor and somatosensory function). Materials and Methods: Periodical interprofessional meetings conducted to the adaptation of a videogame, requiring the control of a joystick for traveling through a maze, to motor learning principles. In a pilot validation, effects in unilateral upper limb function, gross manual dexterity, and somatosensory thresholds were assessed before and after 10-week training in 13 children with CP. Results: After 10-week training with the adapted serious game, children showed learning rates above 90% and improvement in motor learning parameters along the sessions. Manual dexterity and pronation-supination of the dominant hand improved after training. No significant effects were found on somatosensory thresholds. Conclusion: Serious games are useful as motor learning tools for improving motor function in children with PC. Cooperative work among professionals and users is advisable for designing efficient videogames according to rehabilitation best practices.
Collapse
Affiliation(s)
- Juan D Bautista
- Institute of Health Sciences Research (IUNICS-IdISBa), University of the Balearic Islands, Palma de Mallorca, Spain
| | - Francisco J Perales
- Institute of Health Sciences Research (IUNICS-IdISBa), University of the Balearic Islands, Palma de Mallorca, Spain
- Department of Mathematics and Computer Science, University of the Balearic Islands, Palma de Mallorca, Spain
| | - Silvia Ramis
- Department of Mathematics and Computer Science, University of the Balearic Islands, Palma de Mallorca, Spain
| | - Pedro Montoya
- Institute of Health Sciences Research (IUNICS-IdISBa), University of the Balearic Islands, Palma de Mallorca, Spain
| | - Inmaculada Riquelme
- Institute of Health Sciences Research (IUNICS-IdISBa), University of the Balearic Islands, Palma de Mallorca, Spain
- Department of Nursing and Physiotherapy, University of the Balearic Islands, Palma de Mallorca, Spain
| |
Collapse
|
2
|
Gallego P, Rojas Á, Falcón G, Carbonero P, García-Lozano MR, Gil A, Grande L, Cremades O, Romero-Gómez M, Bautista JD, Del Campo JA. Water-soluble extracts from edible mushrooms (Agaricus bisporus) as inhibitors of hepatitis C viral replication. Food Funct 2019; 10:3758-3767. [PMID: 31179460 DOI: 10.1039/c9fo00733d] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
Hepatitis C virus (HCV) is the main agent responsible for chronic liver disease. Recent advances in anti-HCV treatment strategies have significantly increased the viral clearance rate (>90%). However, sustained antiviral responses vary in different cohorts, and high costs limit the broad use of direct-acting antivirals (DAAs). The goal of this study is to evaluate the inhibitory ability of well characterized (LC-QTOF-MS/MS) aqueous extracts obtained from edible mushrooms (Agaricus bisporus) to diminish HCV viral replication. Our data have demonstrated an in vitro inhibitory effect of A. bisporus extracts on NS3/4A protease and HCV replication. Fractionation by ultra-filtration and sequential liquid-liquid extraction showed that the compounds responsible for the inhibition are water-soluble with low molecular weights (<3 kDa) and that action could be through the following five compounds: ergothioneine, adenine, guanine, hypoxanthine, and xanthine, which are present in all fractions (UF-3, AqF-3 kDa and organic fractions) showing NS3/4A inhibition. Low molecular weight aqueous extracts (<3 kDa) from A. bisporus have potential applications in the prophylaxis and treatment of HCV, especially for patients who do not have access to the last generation of DAAs. They may be useful as well for other flaviviruses, which also possess a NS3 serine protease.
Collapse
Affiliation(s)
- Paloma Gallego
- Unit for Clinical Management of Digestive Diseases and CIBERehd, Valme University Hospital, Seville, Spain.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
3
|
Rojas Á, Gallego P, Gil-Gómez A, Muñoz-Hernández R, Rojas L, Maldonado R, Gallego R, García-Valdecasas M, Del Campo JA, Bautista JD, Romero-Gómez M. Natural Extracts Abolished Lipid Accumulation in Cells Harbouring non-favourable PNPLA3 genotype. Ann Hepatol 2018; 17:242-249. [PMID: 29469041 DOI: 10.5604/01.3001.0010.8642] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
UNLABELLED Background & aims. G-allele of PNPLA3 (rs738409) favours triglycerides accumulation and steatosis. In this study, we examined the effect of quercetin and natural extracts from mushroom and artichoke on reducing lipid accumulation in hepatic cells. MATERIAL AND METHODS Huh7.5 cells were exposed to oleic acid (OA) and treated with quercetin and extracts to observe the lipid accumulation, the intracellular-TG concentration and the LD size. Sterol regulatory element binding proteins-1 (SREBP-1), peroxisome proliferator-activated receptor (PPARα-γ) and cholesterol acyltransferase (ACAT) gene expression levels were analysed. RESULTS Quercetin decreased the intracellular lipids, LD size and the levels of intracellular-TG through the down-regulation of SREBP-1c, PPARγ and ACAT1 increasing PPARα. The natural-extracts suppressed OA-induced lipid accumulation and the intracellular-TG. They down-regulate the hepatic lipogenesis through SREBP-1c, besides the activation of lipolysis through the increasing of PPARα expression. CONCLUSIONS Quercetin and the aqueous extracts decrease intracellular lipid accumulation by down-regulation of lipogenesis and up-regulation of lipolysis.
Collapse
Affiliation(s)
- Ángela Rojas
- Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville, Spain. Laboratorio de Investigación clínica y traslacional en enfermedades hepáticas y digestivas y CIBERehd. Instituto de Biomedicina de Sevilla (IBiS)
| | - Paloma Gallego
- Hospital Universitario de Valme, Sevilla, Spain. UGC de enfermedades hepáticas y digestivas, CIBERehd
| | - Antonio Gil-Gómez
- Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville, Spain. Gil-Gómez
| | - Rocío Muñoz-Hernández
- Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville, Spain. Laboratorio de Investigación clínica y traslacional en enfermedades hepáticas y digestivas y CIBERehd. Instituto de Biomedicina de Sevilla (IBiS)
| | - Lourdes Rojas
- Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville, Spain. Laboratorio de Investigación clínica y traslacional en enfermedades hepáticas y digestivas y CIBERehd. Instituto de Biomedicina de Sevilla (IBiS)
| | - Rosario Maldonado
- Hospital Universitario de Valme, Seville, Spain. Unidad de Farmacología Clínica y Experimental
| | - Rocío Gallego
- Laboratorio de Investigación clínica y traslacional en enfermedades hepáticas y digestivas y CIBERehd. Instituto de Biomedicina de Sevilla (IBiS). Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville, Spain
| | - Marta García-Valdecasas
- Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville, Spain. Laboratorio de Investigación clínica y traslacional en enfermedades hepáticas y digestivas y CIBERehd. Instituto de Biomedicina de Sevilla (IBiS)
| | - José A Del Campo
- Hospital Universitario de Valme, Sevilla, Spain. UGC de enfermedades hepáticas y digestivas, CIBERehd
| | - Juan D Bautista
- Universidad de Sevilla, Seville, Spain. Departamento de Bioquímica y Biología Molecular, Facultad de Farmacia
| | - Manuel Romero-Gómez
- Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville, Spain. Laboratorio de Investigación clínica y traslacional en enfermedades hepáticas y digestivas y CIBERehd. Instituto de Biomedicina de Sevilla (IBiS)
| |
Collapse
|
4
|
Rojas Á, Del Campo JA, Clement S, Lemasson M, García-Valdecasas M, Gil-Gómez A, Ranchal I, Bartosch B, Bautista JD, Rosenberg AR, Negro F, Romero-Gómez M. Effect of Quercetin on Hepatitis C Virus Life Cycle: From Viral to Host Targets. Sci Rep 2016; 6:31777. [PMID: 27546480 PMCID: PMC4992894 DOI: 10.1038/srep31777] [Citation(s) in RCA: 66] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2016] [Accepted: 07/26/2016] [Indexed: 12/13/2022] Open
Abstract
Quercetin is a natural flavonoid, which has been shown to have anti hepatitis C virus (HCV) properties. However, the exact mechanisms whereby quercetin impacts the HCV life cycle are not fully understood. We assessed the effect of quercetin on different steps of the HCV life cycle in Huh-7.5 cells and primary human hepatocytes (PHH) infected with HCVcc. In both cell types, quercetin significantly decreased i) the viral genome replication; ii) the production of infectious HCV particles and iii) the specific infectivity of the newly produced viral particles (by 85% and 92%, Huh7.5 and PHH respectively). In addition, when applied directly on HCV particles, quercetin reduced their infectivity by 65%, suggesting that it affects the virion integrity. Interestingly, the HCV-induced up-regulation of diacylglycerol acyltransferase (DGAT) and the typical localization of the HCV core protein to the surface of lipid droplets, known to be mediated by DGAT, were both prevented by quercetin. In conclusion, quercetin appears to have direct and host-mediated antiviral effects against HCV.
Collapse
Affiliation(s)
- Ángela Rojas
- UCM Digestive Diseases, Virgen Macarena-Virgen del Rocío University Hospitals and CIBERehd, Institute of Biomedicine, University of Sevilla, Sevilla, Spain.,Unit for the Clinical Management of Digestive Diseases, Hospital Universitario Valme de Sevilla, Sevilla, Spain
| | - Jose A Del Campo
- Unit for the Clinical Management of Digestive Diseases, Hospital Universitario Valme de Sevilla, Sevilla, Spain
| | - Sophie Clement
- Division of Clinical Pathology, University Hospital, Geneva, Switzerland
| | | | - Marta García-Valdecasas
- UCM Digestive Diseases, Virgen Macarena-Virgen del Rocío University Hospitals and CIBERehd, Institute of Biomedicine, University of Sevilla, Sevilla, Spain.,Unit for the Clinical Management of Digestive Diseases, Hospital Universitario Valme de Sevilla, Sevilla, Spain
| | - Antonio Gil-Gómez
- UCM Digestive Diseases, Virgen Macarena-Virgen del Rocío University Hospitals and CIBERehd, Institute of Biomedicine, University of Sevilla, Sevilla, Spain.,Unit for the Clinical Management of Digestive Diseases, Hospital Universitario Valme de Sevilla, Sevilla, Spain
| | - Isidora Ranchal
- Unit for the Clinical Management of Digestive Diseases, Hospital Universitario Valme de Sevilla, Sevilla, Spain
| | - Birke Bartosch
- Inserm U1052, Cancer Research Centre, University of Lyon, France DevWeCan Laboratories of Excellence Network (Labex), Lyon, France
| | - Juan D Bautista
- Biochemistry and Molecular Biology, Faculty of Pharmacy, University of Sevilla, Spain
| | | | - Francesco Negro
- Division of Clinical Pathology, University Hospital, Geneva, Switzerland.,Division of Gastroenterology and Hepatology, University Hospital, Geneva, Switzerland
| | - Manuel Romero-Gómez
- UCM Digestive Diseases, Virgen Macarena-Virgen del Rocío University Hospitals and CIBERehd, Institute of Biomedicine, University of Sevilla, Sevilla, Spain
| |
Collapse
|
5
|
Abstract
Hepatic encephalopathy is the main cognitive dysfunction in cirrhotic patients associated with impaired prognosis. Hyperammonemia plus inflammatory response do play a crucial role on hepatic encephalopathy. However, in some patients HE appeared without hyperammonemia and patients with increased levels of ammonia could not show cognitive dysfunction. This has led to investigate other factors that could act in a synergistic way. Diabetes mellitus and insulin resistance are characterized by releasing and enhancing these pro-inflammatory cytokines and, additionally, has been related to hepatic encephalopathy. Indeed, patients with diabetes showed raised risk of over hepatic encephalopathy in comparison with non-cirrhotics. Type 2 diabetes mellitus could impair hepatic encephalopathy by different mechanisms that include: a) increasing glutaminase activity; b) impairing gut motility and promoting constipation, intestinal bacterial overgrowth and bacterial translocation. Despite of insufficient clarity about the practicability of anti-diabetic therapy and the most efficacious therapy, we would have to pay a special attention to the management of type 2 diabetes mellitus and insulin resistance in cirrhotic patients.
Collapse
Affiliation(s)
- Javier Ampuero
- Unit for Clinical Management of Digestive Diseases and CIBERehd, Hospital Universitario de Valme, University of Sevilla, Avenida de Bellavista s/n, Sevilla 41014, Spain
| | | | | | | | | | | |
Collapse
|
6
|
Ampuero J, Ranchal I, Nuñez D, Díaz-Herrero MDM, Maraver M, del Campo JA, Rojas Á, Camacho I, Figueruela B, Bautista JD, Romero-Gómez M. Metformin inhibits glutaminase activity and protects against hepatic encephalopathy. PLoS One 2012; 7:e49279. [PMID: 23166628 PMCID: PMC3499552 DOI: 10.1371/journal.pone.0049279] [Citation(s) in RCA: 43] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2012] [Accepted: 10/08/2012] [Indexed: 12/11/2022] Open
Abstract
AIM To investigate the influence of metformin use on liver dysfunction and hepatic encephalopathy in a retrospective cohort of diabetic cirrhotic patients. To analyze the impact of metformin on glutaminase activity and ammonia production in vitro. METHODS Eighty-two cirrhotic patients with type 2 diabetes were included. Forty-one patients were classified as insulin sensitizers experienced (metformin) and 41 as controls (cirrhotic patients with type 2 diabetes mellitus without metformin treatment). Baseline analysis included: insulin, glucose, glucagon, leptin, adiponectin, TNFr2, AST, ALT. HOMA-IR was calculated. Baseline HE risk was calculated according to minimal hepatic encephalopathy, oral glutamine challenge and mutations in glutaminase gene. We performed an experimental study in vitro including an enzymatic activity assay where glutaminase inhibition was measured according to different metformin concentrations. In Caco2 cells, glutaminase activity inhibition was evaluated by ammonia production at 24, 48 and 72 hours after metformina treatment. RESULTS Hepatic encephalopathy was diagnosed during follow-up in 23.2% (19/82): 4.9% (2/41) in patients receiving metformin and 41.5% (17/41) in patients without metformin treatment (logRank 9.81; p=0.002). In multivariate analysis, metformin use [H.R.11.4 (95% CI: 1.2-108.8); p=0.034], age at diagnosis [H.R.1.12 (95% CI: 1.04-1.2); p=0.002], female sex [H.R.10.4 (95% CI: 1.5-71.6); p=0.017] and HE risk [H.R.21.3 (95% CI: 2.8-163.4); p=0.003] were found independently associated with hepatic encephalopathy. In the enzymatic assay, glutaminase activity inhibition reached 68% with metformin 100 mM. In Caco2 cells, metformin (20 mM) decreased glutaminase activity up to 24% at 72 hours post-treatment (p<0.05). CONCLUSIONS Metformin was found independently related to overt hepatic encephalopathy in patients with type 2 diabetes mellitus and high risk of hepatic encephalopathy. Metformin inhibits glutaminase activity in vitro. Therefore, metformin use seems to be protective against hepatic encephalopathy in diabetic cirrhotic patients.
Collapse
Affiliation(s)
- Javier Ampuero
- Unit for Clinical Management of Digestive Diseases and CIBERehd, Hospital Universitario de Valme, University of Sevilla, Sevilla, Spain
| | - Isidora Ranchal
- Unit for Clinical Management of Digestive Diseases and CIBERehd, Hospital Universitario de Valme, University of Sevilla, Sevilla, Spain
| | - David Nuñez
- Unit for Clinical Management of Digestive Diseases and CIBERehd, Hospital Universitario de Valme, University of Sevilla, Sevilla, Spain
| | | | - Marta Maraver
- Unit for Clinical Management of Digestive Diseases and CIBERehd, Hospital Universitario de Valme, University of Sevilla, Sevilla, Spain
| | - José Antonio del Campo
- Unit for Clinical Management of Digestive Diseases and CIBERehd, Hospital Universitario de Valme, University of Sevilla, Sevilla, Spain
| | - Ángela Rojas
- Unit for Clinical Management of Digestive Diseases and CIBERehd, Hospital Universitario de Valme, University of Sevilla, Sevilla, Spain
| | - Inés Camacho
- Unit for Clinical Management of Digestive Diseases and CIBERehd, Hospital Universitario de Valme, University of Sevilla, Sevilla, Spain
| | - Blanca Figueruela
- Unit for Clinical Management of Digestive Diseases and CIBERehd, Hospital Universitario de Valme, University of Sevilla, Sevilla, Spain
| | - Juan D. Bautista
- Department of Molecular Biology, University of Sevilla, Sevilla, Spain
| | - Manuel Romero-Gómez
- Unit for Clinical Management of Digestive Diseases and CIBERehd, Hospital Universitario de Valme, University of Sevilla, Sevilla, Spain
| |
Collapse
|
7
|
Romero-Gómez M, Ramos-Guerrero R, Grande L, de Terán LC, Corpas R, Camacho I, Bautista JD. Intestinal glutaminase activity is increased in liver cirrhosis and correlates with minimal hepatic encephalopathy. J Hepatol 2004; 41:49-54. [PMID: 15246207 DOI: 10.1016/j.jhep.2004.03.021] [Citation(s) in RCA: 80] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/01/2003] [Revised: 02/08/2004] [Accepted: 03/26/2004] [Indexed: 12/13/2022]
Abstract
BACKGROUND/AIMS We performed the current study to assess the intestinal activity of enterocyte phosphate-activated glutaminase (PAG) in cirrhosis. METHODS Forty-nine cirrhotic patients and 36 control subjects underwent endoscopic duodenal biopsies. Minimal hepatic encephalopathy (MHE) was evaluated using three psychometric tests. Oral glutamine challenge (OGC) was performed and MELD, Child-Pugh and the presence of esophageal varices were recorded. PAG was measured by enzymatic methods. Cerebral magnetic resonance spectroscopy was performed in 10 cirrhotics. RESULTS PAG was found to be higher in cirrhotics than control subjects 2.4+/-1.51 vs. 0.68+/-0.57IU/mg protein (P<0.001). PAG was also increased in patients with MHE and correlated with MELD, INR, esophageal varices and serum bile acids. A negative correlation was observed between PAG activity and intra-cerebral choline/creatine ratio (r=-0.67; P=0.035) and a positive correlation with glutamine plus glutamate/creatine ratio (r=0.78; P=0.007). In multivariate analysis using backward logistic regression, presence of MHE was the only variable independently related to altered enterocyte PAG. CONCLUSIONS Enterocyte PAG is increased in cirrhotic patients and correlates with MHE. These data support a possible role for intestinal glutaminase in the pathogenesis of hepatic encephalopathy (HE) and could be a new target for future therapies.
Collapse
Affiliation(s)
- Manuel Romero-Gómez
- Hepatology Unit, Hospital Universitario de Valme, Ctra Cádiz s/n, 41014 Sevilla, Spain.
| | | | | | | | | | | | | |
Collapse
|
8
|
Romero Gómez M, Bautista JD, Grande L, Ramos Guerrero RM, Sánchez Muñoz D. [New concepts in the physiopathology of hepatic encephalopathy and therapeutic prospects]. Gastroenterol Hepatol 2004; 27 Suppl 1:40-8. [PMID: 15195533] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/29/2023]
Affiliation(s)
- M Romero Gómez
- Unidad de Hepatología, Hospital Universitario de Valme, Ctra. Cádiz, s/n, 41014 Sevilla, España.
| | | | | | | | | |
Collapse
|